Joseph G. Pressey · A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
Follow
Article1 min read·Published May 2025

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · May 2025 · 1 min read

In brief

In brief

Phase 1/2 trial evaluating lenvatinib combined with everolimus in children and young adults with recurrent solid tumors. The combination demonstrated manageable toxicity at 11 mg/m² lenvatinib plus 3 mg/m² everolimus, with limited objective responses but some prolonged disease control in Ewing sarcoma patients.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Introduction: Developing targeted therapies with manageable toxicities remains a high priority for pediatric cancer. We sought to determine the recommended Phase 2 dose (RP2D) and evaluate the antitumor activity of lenvatinib+everolimus in children/young adults with select recurrent/refractory solid tumors. Methods: Patients 2-21 years old were eligible. Phase 1 used a rolling-six design. Phase 2 was limited to patients with Ewing sarcoma (EWS), rhabdomyosarcoma (RMS), or high-grade glioma (HGG), and ≤2 prior VEGF/VEGFR-targeted therapies. Primary endpoints included the determination of maximum tolerated dose (MTD), RP2D, safety/toxicity (Phase 1), and objective response rate (ORR) per RECIST version 1.1 (RANO for HGG) at Week 16 (Phase 2). Results: In Phase 1, 23 patients received lenvatinib 11 mg/m2 (dose level [DL] 1, n = 18) or 8 mg/m2 (DL -1, n = 5) combined with everolimus 3 mg/m2 orally once daily. DL1 was declared the MTD/RP2D given dose-limiting toxicities (proteinuria [n = 1]; hypertriglyceridemia and hypercholesterolemia [n = 1]) observed in two of 12 patients treated at DL1. In Phase 2, 41 patients (EWS, n = 10; RMS, n = 20; HGG, n = 11) were treated with the RP2D. Two patients with RMS experienced partial response by Week 16. No other objective responses were observed. Two patients with EWS experienced prolonged disease control (≥23 weeks). No new safety signals were identified. The safety profile was similar to those of treated adults with renal cell carcinoma.

Statements in this article

  1. Patients aged 2-21 years with select recurrent or refractory solid tumors were eligible for enrollment.

    RecommendationMethods
  2. Phase 2 enrollment was limited to patients with Ewing sarcoma, rhabdomyosarcoma, or high-grade glioma who had received no more than 2 prior VEGF/VEGFR-targeted therapies.

    RecommendationMethods
  3. The recommended Phase 2 dose was lenvatinib 11 mg/m2 combined with everolimus 3 mg/m2 orally once daily.

    RecommendationResults
  4. Dose-limiting toxicities at the 11 mg/m2 lenvatinib dose level included proteinuria in one patient and hypertriglyceridemia with hypercholesterolemia in one patient, occurring in 2 of 12 patients treated.

    ResearchResults
  5. Two patients with rhabdomyosarcoma experienced partial response by Week 16.

    ResearchResults
  6. Two patients with Ewing sarcoma experienced prolonged disease control lasting at least 23 weeks.

    ResearchResults
  7. No objective responses were observed in patients with Ewing sarcoma or high-grade glioma by Week 16.

    ResearchResults
  8. The safety profile in pediatric and young adult patients was similar to that observed in adults with renal cell carcinoma treated with this combination.

    ResearchResults

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.